Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression (Onco-PDL1s/B2M)
Melanoma, Non Small Cell Lung Cancer, Renal Cancer
About this trial
This is an interventional other trial for Melanoma focused on measuring imunotherapy, biomarkers, prognostic
Eligibility Criteria
Inclusion Criteria:
- Adult patient, male or female, with metastatic cancer of the non-small cell, renal or malignant melanoma type, eligible for treatment with a first-line immune checkpoint inhibitor (immunotherapy alone or in combination with another immunotherapy, chemotherapy or targeted therapy).
- Affiliation to a Social Security organization
- Able to give informed consent to participate in research.
Exclusion Criteria:
- Pregnant women
- Patient under guardianship, curatorship or legal protection
- Patient unable to understand the protocol (language barrier, cognitive difficulties)
- Patient with another active cancer
- Patient with creatinine clearance <60 mL / min
- Patient participating in a therapeutic clinical trial
- Refusal of participation
Sites / Locations
- CHU de Clermont-FerrandRecruiting
Arms of the Study
Arm 1
Other
Metastatic solid tumor treated with first line therapeutic of Immune Checkpoint Inhibitor
The determinations of soluble PDL1 and serum B2M will be taken by blood sample at diagnosis and then every 3 months for 1 year, during a consultation or treatment in an outpatient hospital. The measurement of the tumor PDL1 level at diagnosis will be carried out by immunohistochemistry in the anatomopathology department of Clermont Ferrand University Hospital on the tumor sample that allowed the diagnosis, which does not add an additional sample for the patient. Clinical and imaging examinations will be those conventionally carried out in the context of patient monitoring, the data will only be recorded in the patients' medical files.